

Application/Control Number: 10/780,553

Page 2

Art Unit: 1694

CImpto

02/18/04

B.G.


04/06/06

Claim 1 (Original).

Art Unit: 1694

1. A method for preventing a restenosis at a location of an inflammation in the vasculature of a patient which comprises the steps of:

apportioning a medicament into a plurality of therapeutically effective doses, wherein said medicament is selected from a group consisting of a substituted adenine derivative and a pharmacologically acceptable acid addition salt thereof, said medicament having the formula:



wherein Y is a halogen, each said dose of said medicament being efficacious for responding to said inflammation by reducing monocytes in the blood to below a preselected level; and

administering at least one of said doses to a human in accordance with a predetermined regimen.

2. (Amended) The method as recited in claim 1 wherein Y is [chlonine] chlorine.

Claim 3 – 7 (Original).

3. The method as recited in claim 1 wherein said inflammation results from a catheter procedure.

4. The method as recited in claim 3 wherein said catheter procedure is a percutaneous transluminal angioplasty (PTA) procedure.

5. The method as recited in claim 3 wherein said catheter procedure is selected from a group consisting of an atherectomy procedure, a photolysis procedure and a radio frequency ablation procedure.

6. The method as recited in claim 3 wherein said catheter procedure includes implantation of an arterial stent.

7. The method as recited in claim 1 wherein said predetermined regime comprises the steps of:

preparing fourteen individual portions of said medicament;

administering a first said portion of said medicament to said human prior to a catheter procedure;

administering a second said portion of said medicament to said human subsequent said catheter procedure; and

administering one of said remaining twelve portions of said medicament at consecutive weekly intervals over a twelve week period immediately following said administering of said second said portion of said medicament.

Claims 8 – 15 (Original).

8. The method as recited in claim 7 wherein said first portion of said medicament is administered on the day of said catheter procedure and said second portion of said

medicament is administered on the day immediately following said catheter procedure.


9. The method as recited in claim 7 wherein each said portion of said medicament is approximately one twelve hundredths of a milligram per kilogram of body weight (0.12 mg/Kg).

10. The method as recited in claim 7 wherein said first and second portions of said medicament are administered intravenously, and said remaining portions are administered subcutaneously.

Art Unit: 1694

11. A method for reducing the production of monocytes in a patient to prevent a restenosis wherein said method comprises the steps of:

preparing fourteen individual portions of a medicament, wherein said medicament is selected from a group consisting of a substituted adenine derivative and a pharmacologically acceptable acid addition salt thereof, said medicament having the formula:



wherein Y is a halogen;

administering a first said portion of said medicament to said human prior to a catheter procedure;
providing a second said portion of said medicament to said human subsequent said catheter procedure; and
dispensing one of said remaining twelve portions of said medicament at consecutive weekly intervals over a twelve week period immediately following said administering of said second said portion of said medicament.

12. The method as recited in claim 11 wherein said first portion of said medicament is administered on the day of said catheter procedure and said second portion of said medicament is administered on the day immediately following said catheter procedure.

13. The method as recited in claim 11 wherein each said portion of said medicament is approximately one twelve hundredths of a milligram per kilogram of body weight (0.12 mg/Kg).


14. The method as recited in claim 11 wherein said first and second portions of said medicament are administered intravenously, and said remaining portions are administered subcutaneously.

15. The method as recited in claim 11 wherein Y is chlorine.

Claims 16 – 18 (New).

Art Unit: 1694

16. A method for preventing a restenosis at a location of an inflammation in the vasculature of a patient which comprises the steps of:
apportioning a medicament into a plurality of therapeutically effective doses, wherein said medicament is selected from a group consisting of a substituted adenine derivative and a pharmacologically acceptable acid addition salt thereof, said medicament having the formula:



wherein Y is a halogen, each said dose of said medicament being efficacious for responding to said inflammation by reducing monocytes in the blood to below a preselected level; and
administering at least one of said doses to a human topically with a carrier in accordance with a predetermined regimen.

17. The method as recited in claim 16 wherein said carrier is a stent.

18. The method as recited in claim 16 wherein Y is chlorine.

Application/Control Number: 10/780,553

Art Unit: 1694

Page 9